Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
Werte in diesem Artikel
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Qiagen (QGEN), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This diagnostic products maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 5.66%.For the most recent quarter, Qiagen was expected to post earnings of $0.54 per share, but it reported $0.57 per share instead, representing a surprise of 5.56%. For the previous quarter, the consensus estimate was $0.52 per share, while it actually produced $0.55 per share, a surprise of 5.77%.Price and EPS SurpriseThanks in part to this history, there has been a favorable change in earnings estimates for Qiagen lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Qiagen currently has an Earnings ESP of +2.95%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner.When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf QIAGEN
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf QIAGEN
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu QIAGEN N.V.
Analysen zu QIAGEN N.V.
Datum | Rating | Analyst | |
---|---|---|---|
20.11.2024 | QIAGEN Hold | Jefferies & Company Inc. | |
11.11.2024 | QIAGEN Neutral | UBS AG | |
07.11.2024 | QIAGEN Buy | Deutsche Bank AG | |
07.11.2024 | QIAGEN Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
07.11.2024 | QIAGEN Neutral | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
07.11.2024 | QIAGEN Buy | Deutsche Bank AG | |
07.11.2024 | QIAGEN Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
16.10.2024 | QIAGEN Kaufen | DZ BANK | |
24.09.2024 | QIAGEN Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
11.09.2024 | QIAGEN Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Datum | Rating | Analyst | |
---|---|---|---|
20.11.2024 | QIAGEN Hold | Jefferies & Company Inc. | |
11.11.2024 | QIAGEN Neutral | UBS AG | |
07.11.2024 | QIAGEN Neutral | UBS AG | |
02.08.2024 | QIAGEN Neutral | UBS AG | |
01.08.2024 | QIAGEN Hold | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
17.02.2021 | QIAGEN Verkaufen | Independent Research GmbH | |
14.12.2020 | QIAGEN Verkaufen | DZ BANK | |
10.12.2020 | QIAGEN Verkaufen | Independent Research GmbH | |
24.11.2020 | QIAGEN Verkaufen | Independent Research GmbH | |
11.11.2020 | QIAGEN Verkaufen | DZ BANK |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für QIAGEN N.V. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen